BRUSSELS, 28 August 2026, 12:15 BST — EBM NEWS DESK ANALYSIS — By Katie Winearls
Kimberly-Clark has formally asked European Union regulators to approve its proposed $40bn acquisition of Kenvue, taking one of the consumer goods industry’s biggest deals a step closer to completion.
The US group, best known for brands including Huggies, Kleenex and Kotex, announced plans to acquire Kenvue last November. The deal would bring together a vast portfolio of household and consumer health brands, including Tylenol, Listerine, Neutrogena, Aveeno and Band-Aid. Reuters reported that the proposed transaction has now been submitted to the European Commission for regulatory approval.
Join The European Business Briefing
New subscribers this quarter are entered into a draw to win a Rolex Submariner. Join 40,000+ founders, investors and executives who read EBM every day.
SubscribeIf completed, the acquisition would create a consumer health and personal care giant with roughly $32bn in annual revenue, giving Kimberly-Clark a significantly broader presence across products ranging from nappies and tissue to pain relief, skincare and oral healthcare. The companies have previously said they expect the deal to close during the second half of 2026.
The strategic logic is clear. Consumer goods companies are increasingly looking for scale as they face rising costs, changing consumer behaviour and growing pressure from retailers and private-label competitors. Bringing Kenvue into the Kimberly-Clark portfolio would give the combined business greater purchasing power, a wider global distribution network and a considerably larger collection of established brands.
A $2.1bn savings target
Kimberly-Clark has forecast annual cost savings of approximately $2.1bn from the transaction, underlining how central efficiency gains are to the financial case for the acquisition.
Large consumer brands have increasingly pursued mergers as a way of reducing overlapping costs in areas such as manufacturing, logistics, procurement and administration. But delivering those savings will also be one of the biggest challenges facing management.
Major acquisitions can look compelling on paper while proving far more complicated in practice. Combining global supply chains, corporate cultures and hundreds of brands requires careful execution, particularly when the businesses operate across highly competitive markets.
Kenvue itself brings considerable baggage as well as valuable brands. The company has faced pressure from weaker sales, inflation and legal challenges surrounding Tylenol, creating questions among investors about the risks Kimberly-Clark is taking on.
That makes the EU approval process particularly important. Brussels will assess whether the combination could reduce competition in relevant European consumer markets, although the two companies’ product portfolios are largely complementary rather than directly overlapping.
A changing consumer landscape
For Kimberly-Clark, the acquisition represents a move beyond its traditional strength in personal care and household products.
Kenvue offers exposure to the larger and potentially faster-growing consumer health market, where brand loyalty can be particularly valuable. Products such as Tylenol, Listerine and Neutrogena have established positions with consumers around the world, giving Kimberly-Clark access to categories where health and wellness spending remains a significant long-term growth opportunity.
The deal would also create a company with an extraordinary collection of globally recognised brands under one roof.
Yet scale alone will not guarantee success. Consumers are becoming more price-conscious, private-label products continue to improve and major retailers hold increasing power over manufacturers.
What Comes Next
The European Commission’s decision will be an important milestone, but it is unlikely to be the final challenge facing Kimberly-Clark.
The bigger question will be whether the company can successfully turn a $40bn acquisition into a more profitable and faster-growing business.
If regulators approve the transaction and the integration delivers the promised savings, Kimberly-Clark could emerge as one of the world’s most powerful consumer health and personal care groups.
But with $2.1bn in targeted annual savings to deliver and a complex portfolio of global brands to integrate, the real test will begin after the regulators have finished their work
